Literature DB >> 24738722

The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off.

G M C Masclee1, P M Coloma, M de Wilde, E J Kuipers, M C J M Sturkenboom.   

Abstract

BACKGROUND: Barrett's oesophagus (BO) is a risk factor for oesophageal adenocarcinoma (OAC). Several studies report increasing incidences of BO with substantial variation. AIM: To determine age- and sex-stratified incidence rates (IR) of BO and OAC.
METHODS: Cohort study using two primary care databases in the United Kingdom (UK) and the Netherlands (NL) (2000-2012). BO and OAC cases were identified using disease-specific READ codes (UK) and free-text search with manual validation (NL). Age- and sex-specific incidence rates (IRs) were calculated for both BO and OAC.
RESULTS: From the study population of 6,885,420 subjects in the UK, we identified 12,312 incident BO and 40 (0.3%) subsequent incident OAC cases. There were 1383 incident BO, and subsequent 5 (0.4%) incident OAC cases among the 1,487,191 subjects in the NL. The IR of BO increased linearly with age: 15.6/100,000 PYs (UK) and 23.7/100,000 PYs (NL) for patients aged 40-44 years, increasing to 85.6/100,000 PYs (UK) and 87.0/100,000 PYs (NL) for 70-74 years. In both the UK and the NL, IR of BO was 2-4 times higher in males than females across all age groups. With respect to calendar time, the IR of BO increased by 35% (UK) and 41% (NL) from 2000 to 2003, after which IRs remained stable until 2012.
CONCLUSIONS: The incidence rates of BO in the UK and the NL increased until 2003, but levelled off thereafter. Around 0.3% of patients with BO developed OAC at least 1 year after BO diagnosis. These findings may help tailor endoscopic surveillance strategies among patients with BO.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2014        PMID: 24738722     DOI: 10.1111/apt.12759

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  16 in total

1.  Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs.

Authors:  Gwen M C Masclee; Preciosa M Coloma; Ernst J Kuipers; Miriam C J M Sturkenboom
Journal:  Am J Gastroenterol       Date:  2015-04-28       Impact factor: 10.864

2.  The global prevalence of Barrett's esophagus: A systematic review of the published literature.

Authors:  Inês Marques de Sá; Pedro Marcos; Prateek Sharma; Mário Dinis-Ribeiro
Journal:  United European Gastroenterol J       Date:  2020-07-06       Impact factor: 4.623

Review 3.  [Barrett's esophagus].

Authors:  J Labenz
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

Review 4.  The epidemiology, diagnosis, and treatment of Barrett's carcinoma.

Authors:  Joachim Labenz; Herbert Koop; Andrea Tannapfel; Ralf Kiesslich; Arnulf H Hölscher
Journal:  Dtsch Arztebl Int       Date:  2015-03-27       Impact factor: 5.594

Review 5.  Gender difference in gastro-esophageal reflux diseases.

Authors:  Kiyotaka Asanuma; Katsunori Iijima; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2016-02-07       Impact factor: 5.742

6.  Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030.

Authors:  Melina Arnold; Mathieu Laversanne; Linda Morris Brown; Susan S Devesa; Freddie Bray
Journal:  Am J Gastroenterol       Date:  2017-06-06       Impact factor: 10.864

7.  Barrett's esophagus patients are becoming younger: analysis of a large United States dataset.

Authors:  Takahisa Yamasaki; Sasan Sakiani; Carla Maradey-Romero; Ripple Mehta; Dalbir Sandhu; Stephen Ganocy; Colin Hemond; Mohamed Eisa; Ronnie Fass
Journal:  Esophagus       Date:  2020-01-01       Impact factor: 4.230

8.  'Missed' oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus patients: A large population-based study.

Authors:  Margreet van Putten; Brian T Johnston; Liam J Murray; Anna T Gavin; Damian T McManus; Shivaram Bhat; Richard C Turkington; Helen G Coleman
Journal:  United European Gastroenterol J       Date:  2017-10-11       Impact factor: 4.623

9.  NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.

Authors:  Gwen M C Masclee; Preciosa M Coloma; Manon C W Spaander; Ernst J Kuipers; Miriam C J M Sturkenboom
Journal:  BMJ Open       Date:  2015-01-29       Impact factor: 2.692

10.  A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.

Authors:  Ayesha Noorani; Jan Bornschein; Andy G Lynch; Maria Secrier; Achilleas Achilleos; Matthew Eldridge; Lawrence Bower; Jamie M J Weaver; Jason Crawte; Chin-Ann Ong; Nicholas Shannon; Shona MacRae; Nicola Grehan; Barbara Nutzinger; Maria O'Donovan; Richard Hardwick; Simon Tavaré; Rebecca C Fitzgerald
Journal:  Genome Res       Date:  2017-05-02       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.